E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC |
|
E.1.1.1 | Medical condition in easily understood language |
locally advanced head and neck cancer |
Fortgeschrittene Kopf-Hals Tumoren |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067821 |
E.1.2 | Term | Head and neck cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to explore the feasibility and efficacy in terms of treatment discontinuation due to toxicity and in terms of 1-year progression free survival of a PDL1-Inhibitor plus a CTLA-4 Inhibitor in combination with radiotherapy vs a PDL1-Inhibitor in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HNSCC in the poor prognostic subgroup.
|
Das Primärziel ist die Untersuchung der Machbarkeit und Effektivität (in Bezug auf Behandlungsabbruch aufgrund von Toxizitäten und in Bezug auf das 1 Jahres-progressionsfreien-Überlebens) der Therapie mit einem PDL1- Inhibitor plus einem CTLA-4 Inhibitor in Kombination mit Strahlentherapie und der Therapie mit einem PDL1-Inhibitor in Kombination mit Strahlentherapie als Erstlinientherapie für Patienten mit nicht resektablen lokal fortgeschrittenen HPV negativen Plattenepithelkarzinomen im Kopf- und Halsbereich in dieser Untergruppe mit schlechter Prognose.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to investigate the benefit of the addition of a CTLA-4 Inhibitor and/or a PDL1-Inhibitor to radiotherapy in terms of overall progression free survival, overall survival and to investigate the approach in terms of safety, chronic toxicity and quality of life |
Die Sekundärziele sind die Untersuchung der Vorteile der Hinzunahme eines CTLA-4 Inhibitors und/oder eines PDL1-Inhibitors in Bezug auf das progressionsfreies Überleben und das Gesamtüberleben und die Überprüfung dieses Ansatzes in Bezug auf Sicherheit, chronische Toxizitäten und Lebensqualität. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with locally advanced histopathologically confirmed HNSCC not candidate for primary surgical treatment
No distant metastasis (M0)
Patients that are planned for radiotherapy
Tumor tissue available for central testing Patients with HPV/p16 negative disease (≤70% positively stained cells) as determined by central testing
Adequate normal organ and marrow function
Measurable tumor according to RECIST
Patients must be expected to complete the treatment.
Age > 18 years at time of study entry
Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test upon study entry and be willing to use adequate contraceptive measurements as described in the protocol
Non-sterilized males who are sexually active with a female partner of childbearing potential must be willing to use adequate contraceptive measurements as described in the protocol
|
|
E.4 | Principal exclusion criteria |
•Participation in another clinical study with an investigational product during the last 3 months
•Prior or current anticancer treatment to the head and neck area (e.g. radical attempted or tumor reductive surgery, neo-adjuvant chemotherapy, EGFR inhibitors or radiotherapy).
•Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
•Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
oPatients with vitiligo or alopecia
oPatients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
oAny chronic skin condition that does not require systemic therapy
oPatients without active disease in the last 5 years may be included but only after consultation with the study physician
oPatients with celiac disease controlled by diet alone
•History of primary immunodeficiency
•History of allogeneic organ transplant
•History of another primary malignancy except for
oMalignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence
oAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
oAdequately treated carcinoma in situ without evidence of disease
•History of hypersensitivity to durvalumab or any excipient
•Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
•Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
•Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
•Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control as described in the protocol from screening to 90 days after the last dose of durvalumab monotherapy
•Distant metastasis
•Patients who are institutionalised by official order
•Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia’s Correction
•Receipt of live attenuated vaccination within 30 days prior to study entry step 2 or within 30 days of receiving durvalumab
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints are the 1-year progression free survival composed of the 1-year in-field-progression-free survival and 1-year distant metastasis free survival and the number of treatment discontinuations due to toxicity |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint of the trial will be analysed when data is mature (1 year after last patient has stopped treatment) |
|
E.5.2 | Secondary end point(s) |
Overall Survival
Safety
Chronic toxicity
Quality of life |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoint will be analysed when data are mature (at least 1 year after last patient has stopped treatment) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study occurs when all of the following criteria have been satisfied
1. Thirty days after all enrolled patients have stopped protocol treatment
2. The trial is mature for the analysis of the primary endpoint as defined in the protocol
3. The database has been fully cleaned and frozen for this analysis |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |